Literature DB >> 25173834

Metastasis-promoting role of extravasated platelet activation in tumor.

Tomoharu Miyashita1, Hidehiro Tajima2, Isamu Makino2, Hisatoshi Nakagawara2, Hirohisa Kitagawa2, Sachio Fushida2, John W Harmon3, Tetsuo Ohta2.   

Abstract

BACKGROUND: The last decade has focused attention on the central role of platelets interacting with the tumor cells and the immune system in promoting tumor progression and distant spread through release of growth factors, such as transforming growth factor beta, vascular endothelial growth factor A, and plasminogen activator inhibitor 1, into the tumor microenvironment. We focused on the potential metastasis-promoting role of extravasated platelet aggregation in pancreatic cancer and stroma.
MATERIALS AND METHODS: Resected pancreatic cancer specimens from 40 patients were used in this study. To examine the expression and localization of platelet aggregation in the epithelial-mesenchymal transition (EMT) region in cancer and stroma, CD42b, Snail1, and E-cadherin were assessed using immunohistochemistry. We determined the correlation of these expressed proteins with clinical features.
RESULTS: CD42b expression was detected at the invasive front of the tumor, which was in 73% of the EMT portion, but not in the region of tubular formation. Increased Snail1 and reduction and/or loss of E-cadherin expressions were noted in 85% and 75% of the EMT portion, respectively. There was a significant correlation between CD42b and Snail1 expressions (P = 0.02) and CD42b and reduction and/or loss of E-cadherin expressions (P = 0.008).
CONCLUSIONS: We demonstrate that extravasated platelet aggregation is associated with the first step in the formation of the EMT. These data suggest a potential role for antiplatelet agents to suppress EMT and metastasis by changing the tumor microenvironment.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epithelial-to-mesenchymal transition; Metastasis; Pancreatic cancer; Platelet aggregation

Mesh:

Substances:

Year:  2014        PMID: 25173834     DOI: 10.1016/j.jss.2014.07.037

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  24 in total

1.  Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents.

Authors:  Carlos Zamora; Mariona Riudavets; Margarita Majem; Silvia Vidal; Georgia Anguera; Letícia Alserawan; Ivana Sullivan; Andrés Barba; Jorgina Serra; M Angels Ortiz; Pablo Gallardo; Lidia Perea; Javier Gavira; Agustí Barnadas
Journal:  Cancer Immunol Immunother       Date:  2021-01-02       Impact factor: 6.968

2.  Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.

Authors:  Alison J Gareau; Colin Brien; Simon Gebremeskel; Robert S Liwski; Brent Johnston; Michael Bezuhly
Journal:  Clin Exp Metastasis       Date:  2018-01-11       Impact factor: 5.150

3.  Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1.

Authors:  Lenard M Lichtenberger; Dexing Fang; Roger J Bick; Brian J Poindexter; Tri Phan; Angela L Bergeron; Subhashree Pradhan; Elizabeth J Dial; K Vinod Vijayan
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-20

4.  Hodgkin lymphoma cell lines bind to platelets. Incubation with platelets induces CD15 and P-selectin dependent adhesion of the cell lines to Human Umbilical Vein Endothelial cells (HUVEC).

Authors:  Ofra Malka Ohana; Janet Ozer; Isebrand Prinsloo; Daniel Benharroch; Jacob Gopas
Journal:  Cancer Biol Ther       Date:  2015-09-29       Impact factor: 4.742

5.  Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.

Authors:  Tomoharu Miyashita; Kenji Miki; Takashi Kamigaki; Isamu Makino; Hisatoshi Nakagawara; Hidehiro Tajima; Hiroyuki Takamura; Hirohisa Kitagawa; Sachio Fushida; Ali K Ahmed; Mark D Duncan; John W Harmon; Tetsuo Ohta
Journal:  Clin Exp Med       Date:  2015-10-08       Impact factor: 3.984

6.  Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models.

Authors:  Agnieszka Denslow; Marta Świtalska; Joanna Jarosz; Diana Papiernik; Kseniia Porshneva; Marcin Nowak; Joanna Wietrzyk
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

7.  Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study.

Authors:  Hiroto Saito; Sachio Fushida; Tomoharu Miyashita; Katsunobu Oyama; Takahisa Yamaguchi; Tomoya Tsukada; Jun Kinoshita; Hidehiro Tajima; Itasu Ninomiya; Tetsuo Ohta
Journal:  BMC Cancer       Date:  2017-04-27       Impact factor: 4.430

8.  Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation.

Authors:  Kenichi Miyata; Ai Takemoto; Sakae Okumura; Makoto Nishio; Naoya Fujita
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

Review 9.  Cancer and Thrombosis: The Platelet Perspective.

Authors:  Claire K S Meikle; Clare A Kelly; Priyanka Garg; Leah M Wuescher; Ramadan A Ali; Randall G Worth
Journal:  Front Cell Dev Biol       Date:  2017-01-05

10.  Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer.

Authors:  Biswajit Saha; Tanmay Mathur; James J Tronolone; Mithil Chokshi; Giriraj K Lokhande; Amirali Selahi; Akhilesh K Gaharwar; Vahid Afshar-Kharghan; Anil K Sood; Gang Bao; Abhishek Jain
Journal:  Sci Adv       Date:  2021-07-21       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.